Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07193550 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
A Phase 2 study of Bone Sarcomas, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT07193550 is a Phase 2 study of Bone Sarcomas that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 70 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07193550, a Phase 2 study of Bone Sarcomas, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
To study the treatment efficacy of zanzalintinib monotherapy in patients with advanced and/or metastatic bone sarcomas.
Conditions Studied
Interventions
- DRUG Zanzalintinib
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-12-05 |
| Est. Completion | 2031-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07193550
The ClinicalTrials.gov registry entry for NCT07193550 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bone Sarcomas appearing as the primary indexed condition, and to 1 intervention - of which Zanzalintinib is the first listed.
NCT07193550 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07193550 about?
NCT07193550 is a clinical study titled "A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)". To study the treatment efficacy of zanzalintinib monotherapy in patients with advanced and/or metastatic bone sarcomas.
What is the current status of trial NCT07193550?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2025-12-05. Estimated completion is 2031-10-31.
What conditions does trial NCT07193550 study?
This clinical trial studies the following conditions: Bone Sarcomas.
What interventions are being tested in trial NCT07193550?
The interventions under investigation include: Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT07193550?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07193550 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bone Sarcomas
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.